Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics, Inc. (Nasdaq: INTS) is a late-stage clinical biotechnology company focused on proprietary, immune-based intratumoral cancer therapies. News about Intensity centers on the clinical development of its lead investigational product candidate, INT230-6, corporate milestones, capital raises, and interactions with regulators and the Nasdaq Capital Market.
Company press releases frequently highlight progress in key clinical programs. These include the Phase 3 INVINCIBLE-3 study in specific soft tissue sarcoma subtypes, where INT230-6 is tested as second- or third-line monotherapy against standard-of-care drugs, and the Phase 2 INVINCIBLE-4 study in presurgical triple-negative breast cancer, which evaluates INT230-6 followed by standard-of-care immunochemotherapy versus standard of care alone with pathological complete response as the primary endpoint. Updates have covered enrollment status, dosing regimen adjustments, early safety observations, and notable findings such as a pathological complete response in the first evaluated patient in the INT230-6 cohort of INVINCIBLE-4.
News flow also includes scientific and medical communications, such as publication of the IT-01 Phase 1/2 study results in eBioMedicine, a Lancet Discovery Science journal, and presentations or posters at major oncology meetings like the San Antonio Breast Cancer Symposium. These items describe disease control rates, overall survival data, abscopal effects, immune activation, and pharmacokinetic findings for INT230-6 in advanced solid tumors.
Investors following INTS can also expect announcements on financial results, registered direct offerings, at-the-market equity sales, and updates on cash runway. Additional disclosures cover Nasdaq listing matters, including extensions to regain compliance with minimum bid price rules and stockholder votes on potential reverse stock splits. For those tracking Intensity Therapeutics, this news page provides a centralized view of clinical, scientific, financial, and regulatory developments related to the company and its intratumoral oncology pipeline.
Intensity Therapeutics announced positive data from the INVINCIBLE study, showcasing significant tumor necrosis in early-stage breast cancers resistant to chemotherapy. The trial utilized INT230-6, which demonstrated up to 100% necrosis from a single injection, alongside increased immune cell activity in the tumor microenvironment. No surgical procedures were canceled or delayed due to the treatment. Results will be presented at the 2022 SITC Annual Meeting, indicating INT230-6's potential to alter treatment paradigms for patients awaiting surgery.